Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (40)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kiely, P. D. W.
Right arrow Articles by Johnson, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kiely, P. D. W.
Right arrow Articles by Johnson, D. M.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 631-637
© 2002 British Society for Rheumatology

Original Papers

Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study

P. D. W. Kiely and D. M. Johnson

Department of Rheumatology, St George's Healthcare NHS Trust, Blackshaw Road, London SW17 0QT, UK

Objective. To study the safety and efficacy of infliximab plus leflunomide combination therapy in adult rheumatoid arthritis (RA).

Methods. Twenty patients with active RA received leflunomide 100 mg for 3 days followed by 20 mg daily for 32 weeks. At week 2 all patients started infliximab 3 mg/kg, and received a further four infusions at weeks 4, 8, 16 and 24.

Results. Adverse events led to 11 patients being withdrawn before the end of the study. The commonest adverse event was pruritis associated with an eczematous rash. Other serious reactions included infliximab infusion reactions in four patients and Stevens–Johnson syndrome in one. There was no relationship between the serum concentration of A77 1726, the active metabolite of leflunomide, and adverse events. The mean Disease Activity Score (DAS28) fell from 7.18 at week 0 to 5.18 (P<0.0001, paired t-test) at week 4 and remained between 3.85 and 4.85 up to week 32. In those patients remaining on treatment, more than 80% achieved an ACR20 response from week 8 to week 28, and up to 46% achieved an ACR70 response.

Conclusion. Infliximab plus leflunomide combination therapy appears to be highly efficacious in the treatment of adult RA. However, widespread use may be limited by adverse events, which were common and in some cases severe.

KEY WORDS: Rheumatoid arthritis, Infliximab, Leflunomide, Treatment, Anti-TNF-{alpha} therapy.

Correspondence to: P. D. W. Kiely.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
E Kis, T Nagy, M Jani, E Molnar, J Janossy, O Ujhellyi, K Nemet, K Heredi-Szabo, and P Krajcsi
Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance
Ann Rheum Dis, July 1, 2009; 68(7): 1201 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
L. E. Kristensen, M. C. Kapetanovic, A. Gulfe, M. Soderlin, T. Saxne, and P. Geborek
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register
Rheumatology, April 1, 2008; 47(4): 495 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. Cobo Ibanez, M. Yehia Tayel, A. Balsa Criado, A. Hernandez Sanz, and E. Martin Mola
Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis
Rheumatology, November 1, 2005; 44(11): 1467 - 1468.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Flendrie, M. C. W. Creemers, P. M. J. Welsing, and P. L. C. M. van Riel
The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study
Rheumatology, April 1, 2005; 44(4): 472 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
P. Maddison, P. Kiely, B. Kirkham, T. Lawson, R. Moots, D. Proudfoot, R. Reece, D. Scott, R. Sword, A. Taggart, et al.
Leflunomide in rheumatoid arthritis: recommendations through a process of consensus
Rheumatology, March 1, 2005; 44(3): 280 - 286.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.